Category: Adamas Pharmaceuticals

  • Supernus bulks up its Parkinson’s portfolio with Adamas takeover

    Supernus has boosted its position in central nervous system therapies with a $400 million deal to acquire Adamas Pharma that will add two approved Parkinson’s disease therapies to its stable. The deal will diversify Supernus’ revenues and reduce its reliance on Trokendi XR (topiramate), a drug for migraine prevention and epilepsy that currently accounts for […]

  • Competition for Neurocrine as Gocovri picks up new Parkinson’s indication

    Adamas Pharmaceuticals’ Parkinson’s drug Gocovri has a new indication as an adjunctive treatment for levodopa/carbodopa in patients with Parkinson’s disease experiencing ‘off’ episodes. The new indication brings the drug into direct competition with Ongentys from rival Neurocrine Biosciences, which was approved for the same use last year. Adamas noted that Gocovri (amantadine extended release) already […]